The most common TEAEs (≥3% of patients) in the pooled ensovibep versus placebo arms were increased blood creatinine (4.3% vs 6.0%), increased alanine aminotransferase (3.7% vs 2.0%), increased fibrin D dimer (3.7% vs 3.0%), worsening of COVID-19 (3.3% vs 4.0%), increased aspartate aminotransferase (3.3% vs 2.0%), nasopharyngitis (3.0% vs 5.0%), and increased lipase (3.0% vs 1.0%) (Supplementary Table 6). The gene discussed is GPT; the disease is COVID-19.